Shares of Sun Pharma ended at ₹1,855.9, rising 0.3 %, after the company announced a global licensing deal for lerodalcibep.
Sun Pharma’s filing disclosed an exclusive licence granting the pharma giant rights to commercialise and manufacture the once‑monthly PCSK9 inhibitor outside the US and China, with LIB Therapeutics receiving upfront and milestone payments plus royalties on net sales.
The partnership positions Sun Pharma to access a $3.7 billion market that grew 38 % CAGR to reach nearly $4 billion in Q2 2026, according to IQVIA data, and is projected to hit $7 billion globally by year‑end 2026.
In Europe alone, the PCSK9 market tallied $2.9 billion in 2026, underscoring the high‑growth potential of the segment outside the two largest markets.
With the EU approval of lerodalcibep under the brand name Lyrokaul on September 21, 2026, the company anticipates milestone payments and a revenue stream that could shift its FY‑2027 outlook, which investors will scrutinise at the upcoming Q4 earnings call.
The shares trade on BSE under SUNPHARMA and on NSE under SUNPHARMA.